

# Peter H Wiernik

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7886341/publications.pdf>

Version: 2024-02-01

176  
papers

7,139  
citations

70961

41  
h-index

64668

79  
g-index

181  
all docs

181  
docs citations

181  
times ranked

5362  
citing authors

#	ARTICLE	IF	CITATIONS
1	All-trans-Retinoic Acid in Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 1997, 337, 1021-1028.	13.9	1,006
2	Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission. <i>New England Journal of Medicine</i> , 1998, 339, 1649-1656.	13.9	569
3	All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. <i>Blood</i> , 2002, 100, 4298-4302.	0.6	427
4	Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 4952-4957.	0.8	376
5	Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5404-5409.	0.8	259
6	Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , 2009, 145, 344-349.	1.2	247
7	Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. <i>Blood</i> , 2001, 97, 1514-1516.	0.6	180
8	Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar). <i>Blood</i> , 1999, 93, 787-795.	0.6	141
9	Frozen Autologous Platelet Transfusion for Patients with Leukemia. <i>New England Journal of Medicine</i> , 1978, 299, 7-12.	13.9	120
10	Prolonged venous access for chemotherapy by means of the hickman catheter. <i>Cancer</i> , 2006, 52, 185-192.	2.0	109
11	Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. <i>Journal of Clinical Oncology</i> , 2016, 34, 3544-3553.	0.8	99
12	FACTORS EFFECTING REMISSION AND SURVIVAL IN ADULT ACUTE NONLYMPHOCYTIC LEUKEMIA (ANLL). <i>Medicine (United States)</i> , 1970, 49, 505.	0.4	88
13	Antibody response in patients with acute nonlymphocytic leukemia. <i>Cancer</i> , 1976, 37, 2177-2182.	2.0	85
14	Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. <i>Medical Oncology</i> , 1999, 16, 58-64.	1.2	84
15	Intrathecal n, nâ€², nâ€²-triethylenethiophosphoramidate [thio-tepa (NSC 6396)] in the treatment of malignant meningeal disease.Phase III study. <i>Cancer</i> , 1976, 38, 1471-1475.	2.0	73
16	Long-term survival in acute myeloid leukemia. <i>Cancer</i> , 1997, 80, 2205-2209.	2.0	70
17	Inflammatory Pseudotumor of Spleen. <i>Cancer</i> , 1990, 66, 597-600.	2.0	67
18	Retinoids in Cancer Treatment. <i>Journal of Clinical Pharmacology</i> , 1992, 32, 868-888.	1.0	65

#	ARTICLE	IF	CITATIONS
19	Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. <i>Cancer</i> , 2017, 123, 3141-3149.	2.0	65
20	Acute promyelocytic leukemiaâ€™ clinical management of 15 patients. <i>American Journal of Hematology</i> , 1980, 8, 347-359.	2.0	63
21	Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1998, 15, 50-57.	1.0	62
22	Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 729-734.	1.9	62
23	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2016, 34, 1864-1871.	0.8	61
24	Primary mediastinal choriocarcinoma in the male. <i>Cancer</i> , 1974, 33, 1196-1203.	2.0	59
25	Clinical Experience with Transfusion of Cryopreserved Platelets. <i>British Journal of Haematology</i> , 1976, 34, 377-385.	1.2	59
26	Pseudoautosomal Linkage of Hodgkin Disease. <i>American Journal of Human Genetics</i> , 1999, 65, 1413-1422.	2.6	58
27	Anticipation in familial chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2001, 113, 407-414.	1.2	58
28	Methotrexate pneumonitis induced by intrathecal methotrexate therapy. A case report with pharmacokinetic data. <i>Cancer</i> , 1976, 38, 1529-1534.	2.0	57
29	Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha. <i>Cancer</i> , 1991, 68, 1538-1544.	2.0	56
30	A combined modality approach to the treatment of Hodgkin's disease. Preliminary results of a prospectively randomized clinical trial. <i>Cancer</i> , 1975, 35, 1055-1065.	2.0	55
31	Second neoplasms in patients with chronic lymphocytic leukemia. <i>Current Treatment Options in Oncology</i> , 2004, 5, 215-223.	1.3	53
32	A comparative clinical trial of 5-azacytidine and guanazole in previously treated adults with acute nonlymphocytic leukemia. <i>Cancer</i> , 1976, 38, 36-41.	2.0	52
33	The therapeutic implications of splenic involvement in stage IIIA Hodgkin's disease. <i>Cancer</i> , 1977, 39, 2158-2165.	2.0	52
34	Disseminated strongyloidiasis with central nervous system involvement diagnosed antemortem in a patient with acquired immunodeficiency syndrome and Burkitts lymphoma. <i>Cancer</i> , 1990, 66, 2417-2420.	2.0	52
35	Phenotypic Heterogeneity in Multiple Myeloma Families. <i>Journal of Clinical Oncology</i> , 2005, 23, 685-693.	0.8	52
36	Serum alpha fetoprotein concentration and tumor growth dissociation in a patient with ovarian teratocarcinoma. <i>Cancer</i> , 1973, 31, 835-839.	2.0	51

#	ARTICLE	IF	CITATIONS
37	Granulocyte transfusion therapy and amphotericin B: Adverse reactions?. American Journal of Hematology, 1989, 31, 102-108.	2.0	50
38	Clonal Isolation of Different Strains of Mouse Mammary Tumor Virus-Like DNA Sequences from Both the Breast Tumors and Non-Hodgkin's Lymphomas of Individual Patients Diagnosed with Both Malignancies. Clinical Cancer Research, 2004, 10, 5656-5664.	3.2	50
39	Incidence of thrombocytopenia and serious hemorrhage among patients with solid tumors. Cancer, 1984, 53, 557-562.	2.0	46
40	Age of onset evidence for anticipation in familial non-Hodgkin's lymphoma. British Journal of Haematology, 2000, 108, 72-79.	1.2	46
41	Cardiac monitoring of patients receiving arsenic trioxide therapy. British Journal of Haematology, 2004, 124, 610-617.	1.2	46
42	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer, 2016, 122, 3005-3014.	2.0	45
43	Doxorubicin, cyclophosphamide, and whole body hyperthermia for treatment of advanced soft tissue sarcoma. Cancer, 1984, 53, 2585-2591.	2.0	42
44	Reverse Transcriptase in Leukocytes of Leukemic Patients in Remission. New England Journal of Medicine, 1976, 294, 75-80.	13.9	41
45	Chemotherapy versus chemoimmunotherapy for small-cell undifferentiated carcinoma of the lung. Cancer, 1980, 46, 2543-2549.	2.0	41
46	Adenocarcinoma arising in vulvar breast tissue. Cancer, 1988, 62, 2234-2238.	2.0	41
47	Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 767-775.	2.0	41
48	Role of <sup>67</sup> Ga citrate scanning in the management of non-hodgkin's lymphoma. Cancer, 1975, 36, 1690-1701.	2.0	40
49	All-trans retinoic acid and late relapses in acute promyelocytic leukemia: Very long-term follow-up of the North American Intergroup Study I0129. Leukemia Research, 2013, 37, 795-801.	0.4	40
50	Possible pulmonary toxicity secondary to vinblastine. Cancer, 1982, 50, 2771-2774.	2.0	38
51	Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. Cancer Chemotherapy and Pharmacology, 1994, 34, 266-269.	1.1	38
52	Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma. Biology of Blood and Marrow Transplantation, 2014, 20, 951-959.	2.0	37
53	Granulocyte Transfusions: Evaluation of Factors Influencing Results and a Comparison of Filtration and Intermittent Centrifugation Leukapheresis. British Journal of Haematology, 1978, 38, 121-129.	1.2	36
54	Phase I and II Agents in Cancer Therapy: I. Anthracyclines and Related Compounds. Journal of Clinical Pharmacology, 1986, 26, 491-509.	1.0	36

#	ARTICLE	IF	CITATIONS
55	Anticipation in familial plasma cell dyscrasias. <i>British Journal of Haematology</i> , 1998, 103, 696-703.	1.2	36
56	FLT3 inhibitors for the treatment of acute myeloid leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 429-36, 444.	0.3	36
57	Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. <i>Medical Oncology</i> , 1996, 13, 111-117.	1.2	35
58	Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia. , 1999, 85, 358-367.		35
59	Rare adult acute lymphocytic leukemia with CD56 expression in the ECOG experience shows unexpected phenotypic and genotypic heterogeneity. <i>American Journal of Hematology</i> , 2001, 66, 189-196.	2.0	34
60	New Cancers after Autotransplantations for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 738-745.	2.0	33
61	Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon. <i>Cancer</i> , 1993, 71, 1726-1730.	2.0	31
62	Association of thyroid disease with acute leukemia. <i>American Journal of Hematology</i> , 1992, 39, 102-107.	2.0	28
63	Acute promyelocytic leukemia and pregnancy. A case report. <i>Cancer</i> , 1995, 76, 2237-2241.	2.0	28
64	Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. <i>Investigational New Drugs</i> , 2001, 19, 89-92.	1.2	28
65	Cyclophosphamide plasma and cerebrospinal fluid kinetics with and without dimethyl sulfoxide. <i>Clinical Pharmacology and Therapeutics</i> , 1982, 32, 122-128.	2.3	27
66	Comparable Outcomes in Nonsecretory and Secretory Multiple Myeloma after Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1134-1140.	2.0	27
67	Partially successful treatment of a patient with chronic lymphocytic leukemia and Hodgkin's disease: Case report and literature review. <i>American Journal of Hematology</i> , 2003, 72, 267-273.	2.0	26
68	Lenalidomide-Induced Warm Autoimmune Hemolytic Anemia. <i>Journal of Clinical Oncology</i> , 2006, 24, e59-e59.	0.8	26
69	Adriamycin therapy in advanced mycosis fungoides. <i>Cancer</i> , 1977, 39, 1967-1970.	2.0	22
70	20th Century Advances in Drug Therapy in Oncology Part I. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 1007-1024.	1.0	22
71	Hairy cell leukemia in first cousins and review of the literature. <i>European Journal of Haematology</i> , 2001, 67, 185-188.	1.1	22
72	Lung cancer as a complication of prolonged survival in patients with lymphoma. <i>Medical and Pediatric Oncology</i> , 1982, 10, 331-338.	1.0	21

#	ARTICLE	IF	CITATIONS
73	Phase II clinical trial with 5-fluorouracil, recombinant interferon- $\beta$ -2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus. <i>Cancer</i> , 1996, 78, 30-34.	2.0	21
74	Combination chemotherapy of adult acute lymphocytic leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 1976, 19, 240-245.	2.3	20
75	Monosomy 7 in multilineage and acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1991, 79, 152-155.	1.2	20
76	A phase II trial of CI-921 in advanced malignancies. <i>Investigational New Drugs</i> , 1992, 10, 309-312.	1.2	20
77	Occurrence of Myeloma in a Chronic Lymphocytic Leukemia Patient After Response to Differentiation Therapy with Interleukin-4. <i>Leukemia and Lymphoma</i> , 1996, 23, 617-619.	0.6	20
78	Treatment of advanced untreated Hodgkin's disease with SCAB $\beta$ an alternative to MOPP. <i>Cancer</i> , 1981, 47, 224-228.	2.0	19
79	Therapeutic efficacy and pharmacokinetics of vindesine and vindesine-cisplatin in previously treated patients with non-small cell lung carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1983, 10, 104-108.	1.1	19
80	Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17). <i>Medical Oncology</i> , 2012, 29, 2095-2101.	1.2	19
81	Complete remission in refractory anaplastic adult wilms' tumor treated with cisplatin and etoposide. <i>Cancer</i> , 1991, 67, 956-959.	2.0	18
82	Pulmonary embolus in acute myelocytic leukemia. <i>Cancer</i> , 1969, 24, 581-584.	2.0	17
83	Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission. <i>American Journal of Hematology</i> , 1994, 47, 41-44.	2.0	17
84	Recombinant interferon- $\gamma$ therapy in patients with follicular lymphoma. , 1998, 82, 1821-1830.		17
85	Combination chemotherapy with adriamycin and streptozotocin; I. Clinical results in patients with advanced sarcoma. <i>Clinical Pharmacology and Therapeutics</i> , 1976, 20, 605-610.	2.3	16
86	Leukemic infiltration of the breast in acute lymphocytic leukemia (ALL). <i>Hematology</i> , 2008, 13, 101-106.	0.7	16
87	Familial Hairy Cell Leukemia. <i>Leukemia and Lymphoma</i> , 1998, 29, 193-197.	0.6	15
88	13-cis-retinoic acid in the treatment of elderly patients with acute myeloid leukemia. A phase II pilot study of the eastern cooperative oncology group. <i>Cancer</i> , 1991, 67, 1484-1486.	2.0	14
89	Cerebral infection complicating systemic aspergillosis in acute leukemia: clinical and radiographic presentation. <i>Journal of Neuro-Oncology</i> , 1992, 13, 91-100.	1.4	14
90	Low grade malignant hemangioendothelioma of bone: A disease potentially curable with radiotherapy. <i>Medical and Pediatric Oncology</i> , 1994, 23, 144-148.	1.0	14

#	ARTICLE	IF	CITATIONS
91	Acute leukaemia following renal transplantation. <i>Medical Oncology</i> , 1996, 13, 9-13.	1.2	14
92	Circulating haemopoietic progenitor cells in primary and secondary myelofibrosis: relation to collagen and reticulin fibrosis. <i>European Journal of Haematology</i> , 1999, 62, 155-159.	1.1	14
93	Preliminary Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkinâ€™s Lymphoma.. <i>Blood</i> , 2006, 108, 531-531.	0.6	14
94	Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia. <i>Cancer</i> , 2004, 101, 1414-1419.	2.0	13
95	The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1137-1143.	2.0	13
96	Cost analysis of leukemia treatment. A problem-oriented approach. <i>Cancer</i> , 1976, 37, 646-652.	2.0	12
97	Ineffectiveness of chemotherapy in patients with metastatic ependymoma of the cauda equina. <i>Journal of Surgical Oncology</i> , 1983, 22, 33-36.	0.8	12
98	Phase I and II Agents in Cancer Therapy: Two Cisplatin Analogues and Highâ€™Dose Cisplatin in Hypertonic Saline or With Thiosulfate Protection. <i>Journal of Clinical Pharmacology</i> , 1987, 27, 357-365.	1.0	12
99	Effect of histocompatibility factors on pulmonary retention of indium-111-labeled granulocytes. <i>American Journal of Hematology</i> , 1990, 33, 238-243.	2.0	12
100	Familial Erythroleukemia: A Distinct Clinical and Genetic Type of Familial Leukemias. <i>Leukemia and Lymphoma</i> , 1998, 30, 395-401.	0.6	12
101	Plasmacytoid blast crisis in B-cell chronic lymphocytic leukemia: Effect of estradiol on growth and differentiation in vitro. <i>Leukemia Research</i> , 1985, 9, 19-29.	0.4	11
102	Clostridium cadaveris bacteremia in the immunocompromised host. <i>Medical and Pediatric Oncology</i> , 1993, 21, 70-72.	1.0	11
103	Early Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Indolent Non-Hodgkinâ€™s Lymphoma.. <i>Blood</i> , 2006, 108, 2482-2482.	0.6	11
104	Phase II trial of merbarone in patients with malignant brain tumors. <i>Medical Oncology</i> , 1997, 14, 159-162.	1.2	10
105	Treatment of Hematologic Neoplasms with New Immunomodulatory Drugs (IMiDs). <i>Current Treatment Options in Oncology</i> , 2009, 10, 1-15.	1.3	10
106	Long-Term Progression-Free Survival of Patients with Metastatic Melanoma or Renal Cell Carcinoma following High-Dose Interleukin-2. <i>Journal of Investigative Medicine</i> , 2021, 69, 888-892.	0.7	10
107	Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 194, 309-318.	1.2	10
108	Lenalidomide Response in Relapsed/Refractory Aggressive Non-Hodgkinâ€™s Lymphoma Is Related to Tumor Burden and Time from Rituximab Treatment.. <i>Blood</i> , 2007, 110, 2565-2565.	0.6	10

#	ARTICLE	IF	CITATIONS
109	A phase II study of intravenously-administered methyl CCNU in the treatment of advanced sarcomas. <i>Cancer</i> , 1976, 37, 615-619.	2.0	9
110	Treatment of adult patients with acute lymphocytic leukemia in relapse. <i>Leukemia and Lymphoma</i> , 1996, 20, 317-319.	0.6	9
111	The influence of parental age and gender on anticipation in familial B-Cell malignancies. <i>Medical Oncology</i> , 2007, 24, 55-62.	1.2	9
112	At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial. <i>British Journal of Haematology</i> , 2020, 191, 37-43.	1.2	9
113	The Significance of Abnormal Circulating Cells in Patients with Hodgkin's Disease. <i>British Journal of Haematology</i> , 1975, 31, 177-183.	1.2	8
114	Hypertrophic pulmonary osteoarthropathy and metastases from a malignant fibrous histiocytoma. <i>Cancer</i> , 1980, 45, 595-598.	2.0	8
115	Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: A study of the Eastern Cooperative Oncology Group (E1993). <i>Leukemia and Lymphoma</i> , 2005, 46, 377-385.	0.6	8
116	Phase II Study of Interleukin-4 in Indolent B-cell Non-Hodgkin Lymphoma and B-cell Chronic Lymphocytic Leukemia: A Study of the Eastern Cooperative Oncology Group (E5Y92). <i>Journal of Immunotherapy</i> , 2010, 33, 1006-1009.	1.2	8
117	Lenalidomide in lymphomas and chronic lymphocytic leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 475-488.	0.9	8
118	Androgen Therapy for Acute Myeloid and Hairy Cell Leukemia. <i>Current Treatment Options in Oncology</i> , 2018, 19, 4.	1.3	8
119	Serum CA125 and PSA concentrations in patients with lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 527-31.	0.3	8
120	Initial Observations on the Effects of $\delta^9$ -Tetrahydrocannabinol on the Plasma Pharmacokinetics of Cyclophosphamide and Doxorubicin. <i>Journal of Clinical Pharmacology</i> , 1981, 21, 90S-98S.	1.0	7
121	Hydrocele following treatment for Hodgkin's disease. <i>Cancer</i> , 1982, 50, 305-307.	2.0	7
122	The association between breast cancer and lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2005, 3, 695-6.	0.3	7
123	Porphyria cutanea tarda in a patient with acute leukemia. <i>American Journal of Hematology</i> , 1986, 23, 69-75.	2.0	6
124	SMALL BOWEL OBSTRUCTION AS A LATE COMPLICATION OF THE TREATMENT OF HODGKIN'S DISEASE. <i>ANZ Journal of Surgery</i> , 1990, 60, 585-588.	0.3	6
125	Disseminated aspergillosis after fungemia in a patient with extragonadal germ cell tumor undergoing autologous bone marrow transplantation. <i>Cancer</i> , 1991, 68, 1842-1844.	2.0	6
126	Optimal Therapy for Adult Patients with Acute Myeloid Leukemia in First Complete Remission. <i>Current Treatment Options in Oncology</i> , 2014, 15, 171-186.	1.3	6



#	ARTICLE	IF	CITATIONS
127	Pulmonary Langerhans cell histiocytosis, acute myeloid leukemia, and myelofibrosis in a large family and review of the literature. <i>Leukemia Research</i> , 2018, 67, 39-44.	0.4	6
128	Id/KLH Vaccine (Favldâ,ç) Following Treatment with Rituximab: An Analysis of Response Rate Improvement (RRI) and Time-to-Progression (TTP) in Follicular Lymphoma (FL).. <i>Blood</i> , 2004, 104, 587-587.	0.6	6
129	Unique Dermatological Complication of rhM-CSF Treatment. <i>Leukemia and Lymphoma</i> , 1994, 15, 347-349.	0.6	5
130	Objective Response of Multiple Myeloma to Cyclosporin A. <i>Leukemia and Lymphoma</i> , 1994, 16, 167-170.	0.6	5
131	Resolution of massive pleural effusion due to lymphoma with intrapleural interleukinâ€². <i>American Journal of Hematology</i> , 2010, 85, 711-712.	2.0	5
132	Familial Leukemias. <i>Current Treatment Options in Oncology</i> , 2015, 16, 8.	1.3	5
133	Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 581-586.	2.0	5
134	Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 34, 266-269.	1.1	5
135	Late Relapses Following All-Trans Retinoic Acid for Acute Promyelocytic Leukemia Are Uncommon, Respond Well to Salvage Therapy and Occur Independently of Prognostic Factors At Diagnosis: Long-Term Follow-up of North American Intergroup Study I0129. <i>Blood</i> , 2011, 118, 83-83.	0.6	5
136	Long-term (LT) disease-free survival (DFS) of melanoma (MM) and renal cell cancer (RCC) patients following high-dose interleukin-2 (HD IL2).. <i>Journal of Clinical Oncology</i> , 2017, 35, e21005-e21005.	0.8	5
137	Therapeutic effect of cyclosporine A in thrombocytopenia after myeloablative chemotherapy in acute myeloid leukaemia. <i>Medical Oncology</i> , 1997, 14, 43-46.	1.2	4
138	Metastatic Choriocarcinoma in a Middle-Aged Man Presenting as a Right Thigh Mass with Venous Thrombosis: A Case Report. <i>Medical Oncology</i> , 2003, 20, 189-194.	1.2	4
139	Radiation therapy compared with chemotherapy for consolidation of chemotherapy-induced remission of advanced Hodgkin lymphoma: a study by the Eastern Co-operative Oncology Group (E1476) with >20 years follow-up. <i>Leukemia and Lymphoma</i> , 2009, 50, 1632-1641.	0.6	4
140	Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493). <i>Leukemia and Lymphoma</i> , 2012, 53, 1137-1142.	0.6	4
141	Treatment-Related Mortality and Relapse Rate from Time of Initiation of Post-Remission Therapy for Patients Receiving Allogeneic Transplantation, Autologous Transplantation or Intensive Chemotherapy: A Report from the Eastern Cooperative Oncology Group (ECOG). <i>Blood</i> , 2008, 112, 49-49.	0.6	4
142	Mutation of Cellular Retinoic Acid-Binding Protein-II (Crabp-II) Does Not Account for Resistance to All-Trans Retinoic Acid (ATRA) in Relapse Acute Promyelocytic Leukemia (APL).. <i>Blood</i> , 2004, 104, 2081-2081.	0.6	4
143	KLHDC8B Is a Novel, Mitotically-Regulated Classical Hodgkinâ€™s Lymphoma Candidate Susceptibility Gene.. <i>Blood</i> , 2006, 108, 473-473.	0.6	4
144	Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. <i>Cancer</i> , 1995, 75, 2782-2784.	2.0	3

#	ARTICLE	IF	CITATIONS
145	A Randomized Trial of Induction Therapy (Daunorubicin, Vincristine, Prednisone versus Daunorubicin,) Tj ETQq1 1 0.784314 rgBT /Overd Long-term Follow-up: An Eastern Cooperative Oncology Group Study (E3486). Leukemia and Lymphoma, 2003, 44, 1515-1521.	0.6	3
146	Active Immunotherapy with FavldÂ® (Id/KLH) Following Rituximab Induction: Long-Term Follow-Up of Response Rate Improvement (RRI) and Disease Progression in Follicular Lymphoma Patients (pts).. Blood, 2006, 108, 691-691.	0.6	3
147	The Pitfalls of Early Publication of Data in Acute Myeloid Leukemia: A Report from the Eastern Cooperative Oncology Group (ECOG).. Blood, 2008, 112, 1952-1952.	0.6	3
148	Methylguazone, Vindesine and Cisplatin for the Treatment of Patients with Relapsed or Refractory Malignant Lymphoma: An Eastern Cooperative Oncology Group Study (PA482). Leukemia and Lymphoma, 1998, 30, 619-624.	0.6	2
149	Bleomycin, Lomustine, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BLEO-CCVPP) in Patients with Hodgkin's Disease who Relapsed after Radiotherapy Alone: a Long-Term Foliow-Up Study of the Eastern Cooperative Oncology Group (E3481). Leukemia and Lymphoma, 2001, 40, 357-363.	0.6	2
150	Reappearance of acute myeloid leukemia after almost 23 years of continuous complete remission. American Journal of Hematology, 2009, 84, 455-457.	2.0	2
151	Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50Âyears. Medical Oncology, 2014, 31, 136.	1.2	2
152	Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Value of Interprofessional Healthâ€Care Teams in Medication Prescribing and Medication Error Prevention. Journal of Clinical Pharmacology, 2018, 58, 843-848.	1.0	2
153	Results from a Phase II Study of Lenalidomide Oral Monotherapy in Relapsed/Refractory Indolent Non-Hodgkinâ€™s Lymphoma.. Blood, 2007, 110, 2560-2560.	0.6	2
154	Acute Lymphoblastic Leukemia of Adulthood: Progress or Not?. Current Treatment Options in Oncology, 2011, 12, 303-311.	1.3	1
155	Diagnosis and Treatment of Adult Acute Myeloid Leukemia Other than Acute Promyelocytic Leukemia. , 2013, , 375-401.		1
156	Plasma cell dyscrasias and leukemias. Cancer Chemotherapy and Biological Response Modifiers, 2005, , 343-389.	0.5	1
157	Lenalidomide Response in Relapsed/Refractory Diffuse Large B-Cell Non-Hodgkinâ€™s Lymphoma.. Blood, 2007, 110, 2564-2564.	0.6	1
158	Initial Results from an International Study in Relapsed/Refractory Aggressive Non-Hodgkinâ€™s Lymphoma To Confirm the Activity, Safety and Criteria for Predicting Response to Lenalidomide Monotherapy.. Blood, 2007, 110, 2572-2572.	0.6	1
159	Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood, 2008, 112, 3314-3314.	0.6	1
160	Plasma cell dyscrasias and leukemias. Cancer Chemotherapy and Biological Response Modifiers, 2005, 22, 343-89.	0.5	1
161	Survival more than 19 years after the diagnosis of accelerated phase of chronic myelocytic leukemia. Clinical Advances in Hematology and Oncology, 2011, 9, 242-8.	0.3	1
162	False positive lymphography in Hodgkin's disease: A histologic-lymphadenographic correlation. Medical and Pediatric Oncology, 1977, 3, 253-259.	1.0	0

#	ARTICLE	IF	CITATIONS
163	The War on Healthcare Professionals and Healthcare Delivery. <i>Cancer Investigation</i> , 1999, 17, 164-169.	0.6	0
164	Plasma cell dyscrasias and leukemias. <i>Update on Cancer Therapeutics</i> , 2006, 1, 539-567.	0.9	0
165	Update: APOR. <i>Clinical and Translational Science</i> , 2011, 4, 399-399.	1.5	0
166	Detection of a new embryonic antigen (ESA-10) in the blood of patients with cancer: preliminary results in the United States. <i>Medical Oncology</i> , 2011, 28, 67-70.	1.2	0
167	Diagnosis and Treatment of Hodgkin's Lymphoma. , 2013, , 985-1013.		0
168	Diagnosis and Treatment of Hodgkin Lymphoma. , 2018, , 903-937.		0
169	Diagnosis and Treatment of Adult Acute Myeloid Leukemia Other than Acute Promyelocytic Leukemia. , 2018, , 375-407.		0
170	Adult hypodiploid B-acute lymphoblastic leukaemia and stem cell transplantation. <i>British Journal of Haematology</i> , 2019, 186, 205-206.	1.2	0
171	Plasma cell myeloma and leukemia. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2003, 21, 365-397.	0.5	0
172	Common Gene Expression Changes in Matched Pretreatment and Relapse Samples from Eastern Cooperative Oncology Group Acute Promyelocytic Leukemia (APL) Patients Treated on the Chemotherapy (C) or All-Trans Retinoic Acid (ATRA)-Containing (A) Randomization Arms of Protocol E2491.. <i>Blood</i> , 2006, 108, 4311-4311.	0.6	0
173	Differential Gene Expression Patterns and Interaction Networks in BCR/ABL Positive and Negative Adult Acute Lymphoblastic Leukemias.. <i>Blood</i> , 2006, 108, 1836-1836.	0.6	0
174	Treatment Type Determines Gene Expression Changes from Pretreatment (PTx) to Relapse (Rel) in Acute Promyelocytic Leukemia (APL).. <i>Blood</i> , 2007, 110, 3167-3167.	0.6	0
175	in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993. <i>Blood</i> , 2015, 126, 795-795.	0.6	0
176	The War on Healthcare Professionals and Healthcare Delivery. <i>Cancer Investigation</i> , 1999, 17, 164-169.	0.6	0